We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

129 hedge funds and large institutions have $204M invested in Celldex Therapeutics in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 44 increasing their positions, 29 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 29

12% more capital invested

Capital invested by funds: $183M → $204M (+$21.5M)

8% more call options, than puts

Call options by funds: $904K | Put options by funds: $837K

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.17% less ownership

Funds ownership: 3.88% → 3.71% (-0.17%)

1% less funds holding

Funds holding: 130 → 129 (-1)

Holders
129
Holders Change
-1
Holders Change %
-0.77%
% of All Funds
3.22%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
18
Increased
44
Reduced
29
Closed
17
Calls
$904K
Puts
$837K
Net Calls
+$67K
Net Calls Change
+$288K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$4.21M
2
AC
Ascend Capital
California
+$3.18M
3
TCMG
TSP Capital Management Group
New Jersey
+$2.9M
4
Citadel Advisors
Citadel Advisors
Florida
+$1.79M
5
MG
Meditor Group
Bermuda
+$1.28M

Top Sellers

Rank Fund Capital Flow
1
CWAM
Columbia Wanger Asset Management
Illinois
-$8.32M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$5.26M
3
FCM
Frontier Capital Management
Massachusetts
-$3.11M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.02M
5
Deutsche Bank
Deutsche Bank
Germany
-$1.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$1.26M +$149K +3,975 +16%
QI
27
QS Investors
New York
$1.23M -$23.4K -624 -2%
Goldman Sachs
28
Goldman Sachs
New York
$1.09M +$411K +10,957 +76%
TCIM
29
TIAA CREF Investment Management
New York
$1.08M +$159K +4,241 +20%
Russell Investments Group
30
Russell Investments Group
United Kingdom
$1.01M +$776K +20,709 +742%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$847K +$509K +13,591 +221%
TA
32
Teachers Advisors
New York
$826K +$2.06K +55 +0.3%
CS
33
Credit Suisse
Switzerland
$669K +$154K +4,107 +36%
HighTower Advisors
34
HighTower Advisors
Illinois
$659K -$150 -4 -0%
Swiss National Bank
35
Swiss National Bank
Switzerland
$583K – – –
Renaissance Technologies
36
Renaissance Technologies
New York
$575K -$368K -9,827 -42%
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$552K -$53.5K -1,428 -10%
California Public Employees Retirement System
38
California Public Employees Retirement System
California
$516K – – –
AllianceBernstein
39
AllianceBernstein
Tennessee
$509K – – –
Invesco
40
Invesco
Georgia
$500K +$8.13K +217 +2%
FCM
41
Frontier Capital Management
Massachusetts
$498K -$3.11M -82,873 -88%
BG
42
Bellevue Group
Switzerland
$458K – – –
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$425K +$2.4K +64 +0.7%
T. Rowe Price Associates
44
T. Rowe Price Associates
Maryland
$419K +$50.2K +1,340 +16%
VEA
45
Virtus ETF Advisers
New York
$400K +$31.9K +852 +10%
Bank of America
46
Bank of America
North Carolina
$378K +$70.4K +1,878 +27%
Jacobs Levy Equity Management
47
Jacobs Levy Equity Management
New Jersey
$332K +$73.7K +1,967 +34%
NFA
48
Nationwide Fund Advisors
Ohio
$320K – – –
D.E. Shaw & Co
49
D.E. Shaw & Co
New York
$306K +$222K +5,910 +478%
TCM
50
Tekla Capital Management
Massachusetts
$303K – – –
1
2
3 4 5

CLDX Hedge Fund Activity: Q3 2017 in Review

129 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2017, worth a combined $204M — up 12% from $183M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CLDX positions and 17 closed out — a net gain of 1 holder — while 44 added to existing stakes and 29 trimmed.

The largest buyer was Millennium Management, adding an estimated $4.21M. The largest seller was Columbia Wanger Asset Management, cutting an estimated $8.32M.

  • 129 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2017, down from 130 in Q2 2017.
  • Funds reported $204M of Celldex Therapeutics stock for Q3 2017, up 12% quarter-over-quarter.
  • 18 funds opened new Celldex Therapeutics positions in Q3 2017 and 17 closed out, a net change of +1 holder.
  • The largest Celldex Therapeutics buyer in Q3 2017 was Millennium Management, an estimated $4.21M added.
  • The largest Celldex Therapeutics seller in Q3 2017 was Columbia Wanger Asset Management, an estimated $8.32M sold.

Based on aggregated 13F filings for Q3 2017.